OncoMatch/Clinical Trials/NCT06046313
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
Is NCT06046313 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Decitabine for and VENCLYXTO for acute myeloid leukemia.
Treatment: Decitabine for · VENCLYXTO — To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Cannot have received: chemotherapy
Treated patients who had received various chemotherapy regiments.
Lab requirements
Kidney function
Creatinine clearance ≥30 mL/min (Cockcroft-Gault or eGFR)
Liver function
AST and ALT ≤3× ULN, total bilirubin ≤2× ULN
Cardiac function
LVEF ≥50% (ECHO); exclusion of uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease (NYHA), or history of myocardial infarction in the 6 months prior to screening
Creatinine clearance ≥30 mL/min (Cockcroft-Gault or eGFR). AST and ALT ≤3× ULN, total bilirubin ≤2× ULN. Echocardiography (ECHO) showed LVEF ≥50% (AHA 2016). Present clinically significant active cardiovascular disease, such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) functional scale, or history of myocardial infarction in the 6 months prior to screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06046313 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify